Navigation Links
Microarray technology for tailoring breast cancer therapy

Microarray technology could be used to tailor therapy according to the individual, and prevent breast cancer patients from having to undergo painful unsuccessful therapies. In a study published in the journal Breast Cancer Research, researchers analysed tumour tissue samples and identified a group of64 genes that can be used to predict a patient's response in the five years after adjuvant therapy for breast cancer. Identifying patients whose breast tumours express these genes could potentially be used to predict which patients would not benefit from adjuvant therapy, and avoid patients being given therapies with the potential of causing more harm than good.

A team of researchers led by Jonas Bergh from the Karolinska Institutet in Stockholm, Sweden, analysed the gene expression profiles of 159 breast cancer patients using DNA microarray analysis. From these samples they identified the genetic signatures shown by 38 patients who had a poor prognosis - defined as relapse or death from any cause within 5 years. The remaining 121 patients were defined as the 'good prognosis' group. The researchers also used gene expression profiling to separate patients who did well with and without adjuvant therapy, and those whose tumours failed to respond to treatment.

An analysis of the genes expressed in the tumours of all 159 patients showed that 64 genes were used to separate the patients with good and poor prognoses.The researchers then tested the predictive value of the group of 64 genes compared with three currently used clinical markers. Using the expression patterns of the 64 genes identified by the researchers gave significantly better(P=0.007) prediction rates than histological grading, tumour stage and age - which are all accepted prognostic markers for breast cancer.

The present lack of criteria to help tailor breast cancer treatment to individual patients indicates a need to develop new techniques for better prediction of how patients will respond
'"/>

Source:Karolinska Institutet


Page: 1 2

Related biology news :

1. Affymetrix Unveils Plans to Double Plant and Animal Genome Microarray Offering
2. Study Demonstrates Gene Expression Microarrays are Comparable and Reproducible
3. Breakthrough Microarray-based Technology for the Study of Cancer
4. Nanogen Issued Patent for Electronic Microarray With Memory
5. Characterizing Skin Cancer by Microarrays
6. Microarrays as phenotype
7. $6.5 Million Grant for Microarray Center at Yale School of Medicine
8. Agilent Technologies Introduces First Commercial Mouse Microarray for Comparative Genomic Hybridization Research
9. Genomatix Microarray Analysis Pipeline achieves Affymetrix GeneChip compatible?status
10. Novel technology detects human DNA mutations
11. Novel antiviral technology inhibits RSV infection in mice
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Microarray technology for tailoring breast cancer therapy

(Date:5/16/2013)... 16, 2013 Integrated Biometrics patented LES ... custom thin film transistor camera introduces Sherlock, a ... image in the smallest and lightest form factor ... F Mobile ID FAP 45, Certified scanner is ... size and weight when compared to optical scanners. ...
(Date:5/16/2013)... 23 million years old give unprecedented insight into ... of the most species-rich groups among the modern ... Bettina Reichenbacher from the Division of Paleontology and ... Sciences at Ludwig-Maximilians-Universitaet (LMU) in Munich / Germany ... which they assign to the group of bony ...
(Date:5/16/2013)... (GWA), where the entirety of an individual,s DNA is ... which can cause health problems is a massively useful ... pose major ethical problems if used incorrectly, say new ... published on line today (16 May 2013) in the ... based on whole genome and on exome* sequencing and ...
Breaking Biology News(10 mins):Paleontology: The eloquence of the otoliths 2Paleontology: The eloquence of the otoliths 3European Society of Human Genetics urges caution over use of new genetic sequencing techniques 2
... awarded today at the IOF WCO-ECCEO10 Congress in Florence ... award honours an individual researcher who has significantly advanced ... work. It underlines an important aspect of IOF,s mission ... to promote medical innovation, scientific excellence and improved care. ...
... director of the Walter and Eliza Hall Institute from ... in the institute,s Molecular Genetics of Cancer division. ... Professor Doug Hilton, said he was delighted Professor Cory ... institute are immensely proud of this latest of Suzanne,s ...
... -- (May 6, 2010) -- With thousands of scientists across ... to fight disease, there,s a growing emphasis on finding the ... research from Rice University and the University of Cambridge suggests ... role in hematopoietic stem cells (HSCs), the self-renewing cells the ...
Cached Biology News:Suzanne Cory becomes first-elected woman president of AAS 2Stem cells: In search of a master controller 2
(Date:5/17/2013)... May 17, 2013 - Elsevier, a world-leading provider of ... announced the publication of a recent study in ... human blastocysts showing that those with an abnormal chromosomal ... they have developed to blastocysts, thereby classifying the risk ... study the same group has undertaken a retrospective study, ...
(Date:5/17/2013)... 2013  Cellular Biomedicine Group (OTCQB: CBMG) today ... the total projected enrollment required for its Phase ... efficacy of the medical technology haMPC (Human Adipose-derived ... To date the trial has had no Severe ... I open label clinical research trial for KOA, ...
(Date:5/17/2013)... Men’s skin is biologically different than women’s skin,( says skin ... known to react more aggressively when hormones change, and acne ... other acne causing factors like P.acnes bacteria and excess dirt ... unsightly acne scars. Adult acne treatment, Probiotic Action shares new ... to reduce and prevent acne scarring. , In order to ...
(Date:5/17/2013)... (PRWEB) May 17, 2013 IAC Industries wants ... a start up laboratory needing to set up and furnish ... to a larger facility within a year’s time. How does ... that the laboratory is temporary? What is efficient and cost-effective? ... modular workstations from IAC Industries. The planners at DisperSol determined ...
Breaking Biology Technology:Breakthrough for IVF? 2Breakthrough for IVF? 3Cellular Biomedicine Group Achieves 50% Enrollment Milestone in Phase I Clinical Trial for Knee Osteoarthritis 2Adult Acne Treatment, Probiotic Action Shares New Insight on Why Men’s Skin Scars from Acne and How to Prevent It 2New Downloadable Success Story: “How To Outfit a Dynamic Lab in Flux” 2
... /PRNewswire-FirstCall/ - Angiotech Pharmaceuticals, Inc. (NASDAQ: ... of a series of new, proprietary Quill(TM) SRS ... invasive, gynecology procedures, including hysterectomies and myomectomies. In ... the United States of which approximately 130,000 were ...
... , , SAN DIEGO, Aug. ... scheduled to present at the Canaccord Adams 29th Annual Global Growth ... 2:00 p.m. Eastern Time. , , (Logo: ... these presentations will be accessible on the Company,s website at ...
... N.J., Aug. 4 DOR BioPharma, Inc., (OTC Bulletin ... company, announced today that the Office of Orphan Products ... (FDA) has granted Orphan Drug Designation to Oral BDP ... symptoms associated with chronic Graft-versus-Host disease (cGVHD) in patients ...
Cached Biology Technology:Angiotech Pharmaceuticals announces launch of Quill SRS product codes for laparoscopic gynecology procedures 2Angiotech Pharmaceuticals announces launch of Quill SRS product codes for laparoscopic gynecology procedures 3Angiotech Pharmaceuticals announces launch of Quill SRS product codes for laparoscopic gynecology procedures 4Angiotech Pharmaceuticals announces launch of Quill SRS product codes for laparoscopic gynecology procedures 5Angiotech Pharmaceuticals announces launch of Quill SRS product codes for laparoscopic gynecology procedures 6Optimer Pharmaceuticals to Present at the Canaccord Adams 29th Annual Global Growth Conference 2DOR BioPharma Receives FDA Orphan Drug Designation for orBec(R) for the Treatment of Chronic Gastrointestinal GVHD 2DOR BioPharma Receives FDA Orphan Drug Designation for orBec(R) for the Treatment of Chronic Gastrointestinal GVHD 3DOR BioPharma Receives FDA Orphan Drug Designation for orBec(R) for the Treatment of Chronic Gastrointestinal GVHD 4DOR BioPharma Receives FDA Orphan Drug Designation for orBec(R) for the Treatment of Chronic Gastrointestinal GVHD 5DOR BioPharma Receives FDA Orphan Drug Designation for orBec(R) for the Treatment of Chronic Gastrointestinal GVHD 6
... Smart Solutions has now entered the next ... by partnering up with Cellomics, Inc. The ... integration of Beckman Coulter‘s automated solutions systems ... biological information at the sub-cellular level. The ...
Immunogen GST fusion protein corresponding to full-length rat JNK3/ SAPK1b. Quality Assurance Routinely evaluated by immunoblot. Stability 2 years at -20°C from date of shipment GenBank A...
... research and biologic production demands on cell ... confirming viable cell populations. Therefore, both cell ... be determined accurately and precisely. The new ... and cost effective means to perform the ...
... modification that plays an important role ... inflammation, cell-to-cell adhesion, and cell signaling. ... based Glycoprotein Isolation Kits, Concanavalin A ... that allow isolation of glycoproteins from ...
Biology Products: